Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy

KAÇMAZ, HÜSEYİN; EKIN, NAZIM; EBİK, BERAT; AYĞAN, MUSTAFA; Tuncel, Elif Tugba; ARPA, Medeni; Yalçın, Kendal

doi:10.14744/hf.2022.2022.0016

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy

Berat EBİK, (Sağlık Bilimleri Üniversitesi , Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi, Gastroenteroloji Anabilim Dalı, Diyarbakır, Türkiye)

MUSTAFA AYĞAN, (Dicle Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Diyarbakır, Türkiye)

Elif Tugba TUNCEL, (Sağlık Bakanlığı Manisa Şehir Hastanesi, Gastroenteroloji Anabilim Dalı, Manisa, Türkiye)

HÜSEYİN KAÇMAZ, (Adıyaman Eğitim Hastanesi, Gastroenteroloji Anabilim Dalı, Adıyaman, Türkiye)

Nazim EKIN, (Sağlık Bilimleri Üniversitesi , Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi, Gastroenteroloji Anabilim Dalı, Diyarbakır, Türkiye)

Medeni ARPA, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Rize, Türkiye)

Kendal YALÇIN (Dicle Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, Diyarbakır, Türkiye)

Hepatology forum

1 0

Yıl: 2022 Cilt: 3 Sayı: 3 Sayfa Aralığı: 82 - 87 Metin Dili: İngilizce DOI: 10.14744/hf.2022.2022.0016 İndeks Tarihi: 22-05-2023

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy

Öz:

Background and Aim: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocel- lular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies. Materials and Methods: The medical data of patients who were diagnosed with HCV and received DAA therapy in two tertiary centers in Turkey were retrospectively collected. Results: Among them, 75 patients (52.4%) were noncirrhotic and 68 pa- tients (47.6%) were cirrhotic. The overall SVR rate was 97.2% (139/143). It was 100% in noncirrhotic and 94.1% in cirrhotic patients. HCC was de- veloped in 5 (7.4%) patients, all of whom had baseline cirrhosis. The annual rate of HCC occurrence was 2.94%, and the 5-year cumulative incidence of HCC was 7.3%. The mean Child-Pugh score (CPS) and Model for End- Stage Liver Disease (MELD) score significantly decreased after DAA treat- ment (CPS 7.0 vs 5.9, p=0.001; MELD 10.8 vs 9.5, p=0.003). Conclusion: There was no significant increase in the rate of HCC in cir - rhotic HCV patients treated with DAAs. This treatment led to a remark- ably high SVR rate and lowered CPS and MELD scores in cirrhotic HCV patients.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. World Health Organization. Web Annex B. WHO estimates of the preva- lence and incidence of hepatitis C virus infection by WHO region, 2015. In: Global hepatitis report 2017. Washington: World Health Organization; 2017.
2. Ng V, Saab S. Effects of a sustained virologic response on outcomes of pa- tients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011;9(11):923- 930.
3. Backus L, Boothroyd DB, Phillips BR, Mole LA. Impact of sustained vi- rologc response to pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: The US Department of Veterans Affairs’ experience. Hepatology 2010;52(Suppl 1):428A.
4. Van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández- Rodríguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017;66(3):485-493.
5. Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol 2016;64(6):1217-1223.
6. D’Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell’Era A, Lam- pertico P, et al. The course of esophageal varices in patients with hepati- tis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther 2011;16(5):677-684.
7. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al; HCV Research UK. Outcomes after successful direct-acting an- tiviral therapy for patients with chronic hepatitis C and decompensated cir- rhosis. J Hepatol 2016;65(4):741-747.
8. Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, et al. Newly diagnosed hepatocellular carcinoma in patients with ad- vanced hepatitis C treated with DAAs: A prospective population study. J Hepatol 2018;69(2):345-352.
9. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histo- logical grading and staging of chronic hepatitis. J Hepatol 1995;22(6):696- 699.
10. Kamath PS, Shah VH. Overview of Cirrhosis. In: Feldman M, Friedman LS, Brandt LJ (editors). Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed. New York: Elseiver; 2020.
11. Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular car- cinoma incidence and mortality. Hepatology 2015;61(1):191-199.
12. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Un- expected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65(4):719-726.
13. Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira P, et al. High incidence of hepatocellular carcinoma following successful in- terferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016;65(5):1070-1071.
14. Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, et al. Unusu- ally high rates of hepatocellular carcinoma after treatment with direct- acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152(4):911-912.
15. Toyoda H, Kumada T, Tada T. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology 2016;64(5):1818-1819.
16. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65(4):727- 733.
17. Villani R, Vendemiale G, Serviddio G. Molecular mechanisms involved in HCC recurrence after direct-acting antiviral therapy. Int J Mol Sci 2018;20(1):49.
18. Hsu SJ, Yang SS, Kao JH. Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? J Formos Med Assoc 2020;119(1 Pt 1):3-11.
19. Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, von Felden J, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology. 2018;154(3):515- 517.e3.
20. Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, et al; HCV-TARGET Study Group. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther 2017;45(1):115- 126.
21. Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post- hepatitis C virus era: Should we change the paradigm? World J Gastroen- terol. 2019;25(29):3929-3940.
22. Degasperi E, D’Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Sof- fredini R, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol 2019;17(6):1183- 1191.e7.
23. Mendizabal M, Piñero F, Ridruejo E, Herz Wolff F, Anders M, Reggiardo V, et al; Educational and Awareness Network (LALREAN). Disease progres- sion in patients with hepatitis C virus infection treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 2020;18(11):2554-2563.e3.
24. Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology 2022;76(1):139-154.

APA	EBİK B, AYĞAN M, Tuncel E, KAÇMAZ H, EKIN N, ARPA M, Yalçın K (2022). Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. , 82 - 87. 10.14744/hf.2022.2022.0016
Chicago	EBİK BERAT,AYĞAN MUSTAFA,Tuncel Elif Tugba,KAÇMAZ HÜSEYİN,EKIN NAZIM,ARPA Medeni,Yalçın Kendal Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. (2022): 82 - 87. 10.14744/hf.2022.2022.0016
MLA	EBİK BERAT,AYĞAN MUSTAFA,Tuncel Elif Tugba,KAÇMAZ HÜSEYİN,EKIN NAZIM,ARPA Medeni,Yalçın Kendal Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. , 2022, ss.82 - 87. 10.14744/hf.2022.2022.0016
AMA	EBİK B,AYĞAN M,Tuncel E,KAÇMAZ H,EKIN N,ARPA M,Yalçın K Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. . 2022; 82 - 87. 10.14744/hf.2022.2022.0016
Vancouver	EBİK B,AYĞAN M,Tuncel E,KAÇMAZ H,EKIN N,ARPA M,Yalçın K Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. . 2022; 82 - 87. 10.14744/hf.2022.2022.0016
IEEE	EBİK B,AYĞAN M,Tuncel E,KAÇMAZ H,EKIN N,ARPA M,Yalçın K "Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy." , ss.82 - 87, 2022. 10.14744/hf.2022.2022.0016
ISNAD	EBİK, BERAT vd. "Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy". (2022), 82-87. https://doi.org/10.14744/hf.2022.2022.0016

APA	EBİK B, AYĞAN M, Tuncel E, KAÇMAZ H, EKIN N, ARPA M, Yalçın K (2022). Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. Hepatology forum, 3(3), 82 - 87. 10.14744/hf.2022.2022.0016
Chicago	EBİK BERAT,AYĞAN MUSTAFA,Tuncel Elif Tugba,KAÇMAZ HÜSEYİN,EKIN NAZIM,ARPA Medeni,Yalçın Kendal Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. Hepatology forum 3, no.3 (2022): 82 - 87. 10.14744/hf.2022.2022.0016
MLA	EBİK BERAT,AYĞAN MUSTAFA,Tuncel Elif Tugba,KAÇMAZ HÜSEYİN,EKIN NAZIM,ARPA Medeni,Yalçın Kendal Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. Hepatology forum, vol.3, no.3, 2022, ss.82 - 87. 10.14744/hf.2022.2022.0016
AMA	EBİK B,AYĞAN M,Tuncel E,KAÇMAZ H,EKIN N,ARPA M,Yalçın K Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. Hepatology forum. 2022; 3(3): 82 - 87. 10.14744/hf.2022.2022.0016
Vancouver	EBİK B,AYĞAN M,Tuncel E,KAÇMAZ H,EKIN N,ARPA M,Yalçın K Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy. Hepatology forum. 2022; 3(3): 82 - 87. 10.14744/hf.2022.2022.0016
IEEE	EBİK B,AYĞAN M,Tuncel E,KAÇMAZ H,EKIN N,ARPA M,Yalçın K "Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy." Hepatology forum, 3, ss.82 - 87, 2022. 10.14744/hf.2022.2022.0016
ISNAD	EBİK, BERAT vd. "Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy". Hepatology forum 3/3 (2022), 82-87. https://doi.org/10.14744/hf.2022.2022.0016